A multivariable prediction model for pegvisomant dosing: monotherapy and in combination with long-acting somatostatin analogues

The Effect of the Exon-3-Deleted Growth Hormone Receptor on Pegvisomant-Treated Acromegaly: A Systematic Review and Meta-Analysis

(2016) Sanne E. Franck et al.   NEUROENDOCRINOLOGY

Long-Term Treatment with Pegvisomant as Monotherapy in Patients with Acromegaly: Experience from Acrostudy

(2015) Pamela Freda et al.   Endocrine Practice

Pegvisomant in combination with long-acting somatostatin analogues in acromegaly: the role of the GH receptor deletion of exon 3

(2015) S E Franck et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Prediction of therapy response in acromegalic patients under pegvisomant therapy within the German ACROSTUDY cohort

(2015) Caroline Sievers et al.   Pituitary

Long-Term Efficacy and Safety of Pegvisomant in Combination With Long-Acting Somatostatin Analogs in Acromegaly

(2014) S. J. C. M. M. Neggers et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Circulating levels of pegvisomant and endogenous growth hormone during prolonged pegvisomant therapy in patients with acromegaly

(2013) Michael Madsen et al.   CLINICAL ENDOCRINOLOGY

A Comprehensive Study of Clinical, Biochemical, Radiological, Vascular, Cardiac, and Sleep Parameters in an Unselected Cohort of Patients With Acromegaly Undergoing Presurgical Somatostatin Receptor Ligand Therapy

(2013) Anand K. Annamalai et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Tumor Shrinkage With Lanreotide Autogel 120 mg as Primary Therapy in Acromegaly: Results of a Prospective Multicenter Clinical Trial

(2013) Philippe J. Caron et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Long-term treatment of somatostatin analog-refractory growth hormone-secreting pituitary tumors with pegvisomant alone or combined with long-acting somatostatin analogs: a retrospective analysis of clinical practice and outcomes

(2013) Antonio Bianchi et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Evaluation of growth hormone (GH) action in mice: Discovery of GH receptor antagonists and clinical indications

(2013) John J. Kopchick et al.   MOLECULAR AND CELLULAR ENDOCRINOLOGY

The Liege Acromegaly Survey (LAS): A new software tool for the study of acromegaly

(2012) Patrick Petrossians et al.   ANNALES D ENDOCRINOLOGIE

Growth Hormone Receptor Variants and Response to Pegvisomant in Monotherapy or in Combination with Somatostatin Analogs in Acromegalic Patients: A Multicenter Study

(2011) M. Filopanti et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Coadministration of lanreotide Autogel and pegvisomant normalizes IGF1 levels and is well tolerated in patients with acromegaly partially controlled by somatostatin analogs alone

(2010) Aart-Jan van der Lely et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

A randomized, controlled, multicentre trial comparing pegvisomant alone with combination therapy of pegvisomant and long-acting octreotide in patients with acromegaly

(2009) Peter J. Trainer et al.   CLINICAL ENDOCRINOLOGY

Combined treatment for acromegaly with long-acting somatostatin analogs and pegvisomant: long-term safety for up to 4.5 years (median 2.2 years) of follow-up in 86 patients

(2009) SJCMM Neggers et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Pituitary-independent effect of octreotide on IGF1 generation

(2009) Ana Pokrajac et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Long-term treatment of acromegalic patients resistant to somatostatin analogues with the GH receptor antagonist pegvisomant: its efficacy in relation to gender and previous radiotherapy

(2009) Mónica Marazuela et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

ACROSTUDY: the first 5 years

(2009) Peter J Trainer   EUROPEAN JOURNAL OF ENDOCRINOLOGY

The Exon 3-Deleted Growth Hormone Receptor Is Associated with Better Response to Pegvisomant Therapy in Acromegaly

(2009) Ignacio Bernabeu et al.   JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM

Acromegaly pathogenesis and treatment

(2009) Shlomo Melmed   JOURNAL OF CLINICAL INVESTIGATION

A meta-analysis of the effect of lowering serum levels of GH and IGF-I on mortality in acromegaly

(2008) I M Holdaway et al.   EUROPEAN JOURNAL OF ENDOCRINOLOGY

Growth hormone receptor polymorphism and the effects of pegvisomant in acromegaly

(2008) Antonio Bianchi et al.   Pituitary

Wide variation in surgical outcomes for acromegaly in the UK

(2007) P. R. Bates et al.   CLINICAL ENDOCRINOLOGY